Salim Baghdadi, MD
Cardiology · Kew Gardens, NYNPI 1952549800
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,989 of the $17,922 with a category attached, or 66.9%. Medtronic accounts for 65.7% of it on its own, with 20 other manufacturers making up the rest. Among cardiology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 539 payments — averaging $33.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$12K
- Biotronik Inc.$2K
- Biosense Webster, Inc.$1K
- Welch Allyn$766
- Actelion Pharmaceuticals US, Inc.$430
- Novartis$350
- plus $1K from 15 others
What the payments were for
- Travel & lodging$5,10728%
- Food & beverage$11,98967%
- Education$600%
- Other$7664%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 394 | $11,768 |
| Biotronik Inc. | 22 | $2,032 |
| Biosense Webster, Inc. | 28 | $1,215 |
| Welch Allyn | 1 | $766 |
| Actelion Pharmaceuticals US, Inc. | 16 | $430 |
| Novartis | 24 | $350 |
| Johnson & Johnson | 13 | $310 |
| Novo Nordisk | 10 | $206 |
| Heartflow, Inc. | 7 | $167 |
| Boston Scientific | 2 | $158 |
| E.r. Squibb & Sons, L.L.C. | 7 | $151 |
| AstraZeneca | 5 | $108 |
| Baxter Healthcare | 1 | $56 |
| Scpharmaceuticals Inc. | 2 | $45 |
| Boehringer Ingelheim | 1 | $33 |
| Kestra Medical Technology Services, Inc. | 1 | $33 |
| Pfizer | 1 | $27 |
| Lexicon Pharmaceuticals, Inc. | 1 | $19 |
| Bristol Myers Squibb | 1 | $19 |
| Abbott | 1 | $16 |
| Chiesi USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Micra$979
- Performa$918
- NONE$766
- Carto 3$535
- AURORA EV-ICD MRI SURESCAN$473
- EVERA MRI XT DR SURESCAN$386
- NUVISION ICE CATHETER$253
- OCTARAY MAPPING CATHETER$245
- Arctic Front$240
- Reveal LINQ$183
- COBALT DR MRI SURESCAN$166
- Acticor 7 VR-T DX$156
- Rivacor$138
- BioMonitor$138
- Solia$138
- Edora$138
- Acticor$138
- WATCHMAN Access System$128
- NA$113
- CartoSound$107
How this compares
$17,922 in reported general payments places this provider in the 90th percentile of 112 cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 171 | $138,279 |
| EntrestoSacubitril/Valsartan | 91 | $83,900 |
| XareltoRivaroxaban | 37 | $29,543 |
| JardianceEmpagliflozin | 35 | $28,441 |
| FarxigaDapagliflozin Propanediol | 13 | $19,035 |
| BrilintaTicagrelor | 18 | $10,851 |
| Metoprolol Succinate | 299 | $3,378 |
| Atorvastatin Calcium | 115 | $1,133 |
| Rosuvastatin Calcium | 97 | $1,048 |
| Furosemide | 170 | $587 |
| Nifedipine ErNifedipine | 38 | $505 |
| Digoxin | 43 | $495 |
| SynthroidLevothyroxine Sodium | 11 | $481 |
| Lisinopril | 80 | $421 |
| Losartan Potassium | 50 | $415 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $27 | $138,279171 claims |
| NovartisEntresto | $350 | $83,90091 claims |
| AstraZenecaFarxiga, Brilinta | $108 | $29,88631 claims |
| Johnson & JohnsonXarelto | $310 | $29,54337 claims |
| Boehringer IngelheimJardiance | $33 | $28,44135 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 112 cardiology providers in New York.
Other cardiology in Kew Gardens
- Felix OviasuGarden City$150K
- David D'agateSmithtown$69K
- Michael SiegalNew York$43K
- Michael AvaricioOzone Park$41K
- Bimalkumar BrahmbhattAmityville$31K
- Michael HappesSmithtown$30K
- Meyer AbittanRoslyn$28K
- Perminder GrewalStony Point$19K
- Paul SapiaRoslyn$19K
- Ralph CaselnovaAmityville$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.